Higher exposure to adjuvant pazopanib was linked with longer disease-free survival, according to a phase 3, randomized, placebo-controlled study involving patients with renal cell carcinoma. Investigators collected blood through concentrations at week 3 or 5 (n=311) and week 16 or 20 (n=250). They looked at how exposure or dose intensity impacted disease-free survival and adverse events. Among the results:

• 9 in every 10 patients with early or late exposure data started on 600 mg.
• Patients in higher early exposure quartiles experienced longer disease-free survival.
• Disease-free survival in patients who achieved early or late exposure >20.5 µg/mL was not reached, vs ~30 months in those who did not achieve such.
• Dose intensity up to week 8 did not correlate with disease-free survival.
• With the exception of hypertension, exposure did not impact adverse events and treatment discontinuation.